Cost regulators for NHS therapies in England and Wales have now issued final guidelines endorsing the use of Roche’s Esbriet to treat patients with idiopathic pulmonary fibrosis (IPF), but only in those with moderate to severe forms of the disease.
Read More
The National Institute for Health and Care Excellence (NICE) it remaining steadfast in its position that Roche’s Esbriet should only be funded by the NHS for patients with moderate forms of the fatal lung scarring disease idiopathic pulmonary fibrosis (IPF).
Read More
Patients in England and Wales with the lung scarring disease idiopathic pulmonary fibrosis will have to wait until their disease has worsened before getting routine NHS access to Roche’s Esbriet.
Read More
